SCHEMBL2318653

SCHEMBL2318653

CN(C)CC(=O)N(c1ccc(F)c(-c2nn(CCN3CCCCC3)cc2-c2ccncc2)c1F)S(=O)(=O)c1cc(F)ccc1F

nearest known ligand 0.32

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 3/20 0.32
PSEN2 P49810 3/20 0.32
APH1B Q8WW43 3/20 0.32
NCSTN Q92542 3/20 0.32
APH1A Q96BI3 3/20 0.32
PSENEN Q9NZ42 3/20 0.32
BRAF P15056 2/20 0.31
MAPK3 P27361 2/20 0.31
MAPK1 P28482 2/20 0.31
MAPK14 Q16539 3/20 0.31
MAPK13 O15264 1/20 0.31
MAPK12 P53778 1/20 0.31
MAPK11 Q15759 1/20 0.31
GPBAR1 Q8TDU6 1/20 0.31
AXL P30530 1/20 0.31
PIK3CA P42336 1/20 0.30
PTGS2 P35354 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14719463 0.92 KIF11 (0.34) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL14108518 0.91 MAPK14 (0.33) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL14719049 0.90 PDE10A (0.34) BRAFMAPK3MAPK1PTGS2
SCHEMBL14719043 0.88 BRAF (0.33) BRAFMAPK3MAPK1MAPK14MAPK13
SCHEMBL2359382 0.88 PSEN1 (0.35) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL14718745 0.87 PSEN1 (0.32) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2358766 0.87 PSEN1 (0.34) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL14719344 0.87 CSNK1D (0.41) BRAFMAPK3MAPK1MAPK14MAPK13
SCHEMBL17836526 0.85 MAPK14 (0.34) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2319177 0.84 PSEN1 (0.33) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528909-B1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-06-22 EP claimed
US-8791265-B2 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-07-29 US claimed
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) 2013-02-28 US claimed
EP-2528909-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2012-12-05 EP claimed
WO-2011092088-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-08-04 WO claimed
EP-2528909-B1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2016-06-22 EP disclosed
US-8791265-B2 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-07-29 US disclosed
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS LSI FINANCING 1 DESIGNATED ACTIVITY COMPANY (IE) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053419-A1 SULFONAMIDO DERIVATIVES OF 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K15, MAP3K19, CDK3 PSEN1 1318/4885PSEN2 1322/4885APH1B 1507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.